КЕРЕКТӨӨ ESTIMATED CONSUMPTION OF ANTIBIOTICS AT THE HOSPITAL LEVEL IN THE KYRGYZ REPUBLIC

Improving the quality of antibiotic use in hospitals is one of the main goals of the World Health Organization (WHO) global action plan to combat antibiotic resistance. Drug use analysis provides insight into clinical use, comparisons across countries, regions and health system settings, and changes in drug use over time. The purpose: was to analyze the consumption of antibiotics using DDD analysis in a multidisciplinary hospital in Bishkek, the Kyrgyz Republic for the period 2016-2019. Materials and research methods. To assess the level of consumption of antibiotics, the WHO-recommended system of “conditional daily doses” (Defined Daily Dose, DDDs) and DDDs per 100 bed-days (DDDh) were used. Results. Consumption and purchases are 8 groups of antibiotics - penicillins, cephalosporins, macrolides, fluoroquinolones, nitroimidazoles, aminoglycosides, carbapenems and glycopeptides. Discussion. During the study period, there is a trend of increased consumption of cephalosporins I, IV generations, penicillins, fluoroquinolones, aminoglycosides, carbapenems and glycopeptides. There is a decrease in the consumption of cephalosporins II, III generations, macrolides, aminoglycosides, nitroimidazoles. The use of the lincosamide group, nitrofurantoin, tetracyclines were limited only in 2017 or 2018. Conclusions. The structure of consumption in a multidisciplinary hospital was dominated by IV generation cephalosporins, fluoroquinolones, carbapenems, glycopeptides, aminoglycosides (mainly amikacin), the widespread use of which can contribute to the formation of microorganisms with multiple resistance. In 2016-2019 there is a positive trend in the consumption of the group of penicillins, cephalosporins of the first generation, nitroimidazoles, nitrofurantoin. An increase in the consumption of levofloxacin by 5.6 times and moxifloxacin by 10 times requires an assessment of their rational use. Revealed positive changes in the consumption of macrolides, which have limited indications for use at the hospital stage.